drugset / Trial / NCT03681483
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
Phase 1
Completed
15 enrolled
Memorial Sloan Kettering Cancer Center
Chugai Pharma USA · collabDana-Farber Cancer Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of RO5126766 at different doses to find out what effects, if any, it has on people with advanced lung cancer who have previously received treatment with a PD-1 or PD-L1 inhibitor.
Timeline
- Start
- 2018-10-31
- Primary completion
- 2024-07-08
- Completion
- 2024-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | 4 mg | Oral |